Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -11.61%1.41B | 8.57%5.44B | 9.43%1.39B | 8.93%1.35B | 6.98%1.39B | 9.50%1.6B | 12.23%5.01B | 194.58%1.27B | -5.73%1.24B | -5.71%1.3B |
Operating revenue | -11.61%1.41B | 8.57%5.44B | 9.43%1.39B | 8.93%1.35B | 6.98%1.39B | 9.50%1.6B | 12.23%5.01B | 194.58%1.27B | -5.73%1.24B | -5.71%1.3B |
Cost of revenue | -21.78%301.6M | 14.22%1.12B | 16.41%292.2M | 4.91%262.9M | 11.05%285.3M | 17.03%385.6M | 35.19%978.4M | 354.05%251M | -1.26%250.6M | -4.64%256.9M |
Gross profit | -8.37%1.11B | 7.20%4.32B | 7.70%1.09B | 9.94%1.09B | 5.97%1.1B | 7.30%1.21B | 7.79%4.03B | 92.06%1.02B | -6.80%992.8M | -5.97%1.04B |
Operating expense | -9.51%701.2M | 11.65%2.84B | 12.39%740.3M | 11.61%697.2M | 10.59%723.4M | 11.10%774.9M | 15.64%2.55B | 98.64%658.7M | 2.26%624.7M | -0.86%654.1M |
Selling and administrative expenses | -4.90%465.7M | 13.06%1.79B | 18.07%491.9M | 10.34%421.4M | 9.84%450.8M | 12.24%489.7M | 16.57%1.58B | 107.26%416.6M | 1.22%381.9M | 0.34%410.4M |
Research and development costs | -10.73%254.6M | 9.36%1.05B | 11.98%271.1M | 4.37%253.4M | 11.86%272.6M | 9.19%285.2M | 14.14%962.9M | 85.38%242.1M | 3.94%242.8M | -2.83%243.7M |
Other operating expenses | ---19.1M | ---300K | ---22.7M | --22.4M | ---- | ---- | ---- | ---- | ---- | ---- |
Operating profit | -6.35%409.9M | -0.41%1.48B | -0.95%353.3M | 7.12%394.3M | -1.90%377.2M | 1.18%437.7M | -3.44%1.49B | 80.97%356.7M | -18.97%368.1M | -13.54%384.5M |
Net non-operating interest income expense | 121.21%36.5M | 102.62%100.5M | 163.10%44.2M | 60.93%24.3M | 70.33%15.5M | 91.86%16.5M | 204.29%49.6M | 112.66%16.8M | 118.84%15.1M | 911.11%9.1M |
Non-operating interest income | ---- | 79.02%120.3M | 86.05%64M | 60.93%24.3M | 70.33%15.5M | ---- | 89.30%67.2M | --34.4M | --15.1M | --9.1M |
Non-operating interest expense | ---- | 12.50%19.8M | ---- | ---- | ---- | ---- | -8.33%17.6M | ---- | ---- | ---- |
Total other finance cost | -121.21%-36.5M | ---- | ---- | ---- | ---- | -91.86%-16.5M | ---- | ---- | ---- | ---- |
Other net income (expense) | 72.10%-12.5M | 80.11%-32.5M | -17.46%-7.4M | -459.09%-15.8M | 94.85%-6.1M | -5.16%-44.8M | -355.15%-163.4M | -198.44%-6.3M | 108.16%4.4M | -720.42%-118.5M |
Gain on sale of security | ---- | 561.29%61.5M | ---- | ---- | ---- | ---- | 9,400.00%9.3M | ---- | ---- | ---- |
Special income (charges) | 69.92%-15.1M | 42.81%-101.4M | -311.11%-40.7M | -1,886.36%-43.7M | 93.31%-8.1M | -13.57%-50.2M | -380.49%-177.3M | -325.00%-9.9M | 95.76%-2.2M | -750.54%-121M |
-Less:Restructuring and merger&acquisition | -89.83%4.2M | 332.82%61M | --28.1M | --32.9M | --0 | 5,800.00%41.3M | -205.22%-26.2M | --0 | --0 | -28.71%-26.9M |
-Less:Other special charges | 22.47%10.9M | -80.15%40.4M | 27.27%12.6M | 390.91%10.8M | -94.52%8.1M | -79.54%8.9M | 1,595.83%203.5M | 115.09%9.9M | -96.58%2.2M | 6,330.43%147.9M |
Other non- operating income (expenses) | -51.85%2.6M | 60.87%7.4M | -394.74%-28.2M | 322.73%27.9M | -20.00%2M | 237.50%5.4M | 318.18%4.6M | -371.43%-5.7M | 430.00%6.6M | 66.67%2.5M |
Income before tax | 5.98%433.9M | 12.80%1.55B | 6.24%390.1M | 3.92%402.8M | 40.53%386.6M | 2.71%409.4M | -9.68%1.37B | 73.70%367.2M | -4.84%387.6M | -40.80%275.1M |
Income tax | 20.38%70.3M | -0.20%152.1M | 32.26%45.1M | -22.77%40.7M | -3.35%20.2M | 0.52%58.4M | -22.05%152.4M | 212.84%34.1M | -17.40%52.7M | -64.15%20.9M |
Net income | 1.54%356.4M | 197.96%4.17B | 3.95%384.3M | 699.95%3.07B | 19.48%365M | 3.08%351M | -8.05%1.4B | -7.20%369.7M | 11.70%383.7M | -24.83%305.5M |
Net income continuous Operations | 3.59%363.6M | 14.43%1.4B | 3.57%345M | 8.12%362.1M | 44.14%366.4M | 3.08%351M | -7.85%1.22B | 66.13%333.1M | -2.50%334.9M | -37.45%254.2M |
Net income discontinuous operations | ---7.2M | 1,446.10%2.77B | 7.38%39.3M | 5,447.75%2.71B | -102.73%-1.4M | ---- | -9.35%179.4M | --36.6M | --48.8M | --51.3M |
Minority interest income | -77.78%-1.6M | -63.33%-4.9M | -550.00%-1.3M | -16.67%-1.4M | 18.75%-1.3M | -900K | -3M | -200K | -1.2M | -1.6M |
Net income attributable to the parent company | 1.73%358M | 197.68%4.17B | 4.24%385.6M | 697.82%3.07B | 19.28%366.3M | 3.35%351.9M | -7.85%1.4B | -7.15%369.9M | 12.05%384.9M | -24.43%307.1M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 1.73%358M | 197.68%4.17B | 4.24%385.6M | 697.82%3.07B | 19.28%366.3M | 3.35%351.9M | -7.85%1.4B | -7.15%369.9M | 12.05%384.9M | -24.43%307.1M |
Basic earnings per share | 5.17%0.61 | 202.16%6.98 | 6.56%0.65 | 715.87%5.14 | 19.61%0.61 | 3.57%0.58 | -6.10%2.31 | -6.15%0.61 | 14.55%0.63 | -21.54%0.51 |
Diluted earnings per share | 5.17%0.61 | 203.04%6.97 | 6.56%0.65 | 714.29%5.13 | 22.00%0.61 | 3.57%0.58 | -5.74%2.3 | -6.15%0.61 | 14.55%0.63 | -23.08%0.5 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |